Aligos Therapeutics, Inc.
ALGS Nasdaq
SEC CIK 1799448
Follow Aligos Therapeutics
Weekly email: filings, results
Revenue, last quarter
$2.8M
+281.9% vs same quarter last year
Net income
−$21.9M
+30.7% vs same quarter last year
EPS, diluted
−$2.09
+31.3% vs same quarter last year
Operating cash flow
$1.5M
+106% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $2.2M | −$24.2M |
| FY24 | $3.6M | −$131.2M |
| FY23 | $6.2M | −$87.7M |
| FY22 | $0 | −$96M |
| FY21 | $0 | −$128.3M |
| FY20 | $0 | −$108.5M |
| FY19 | - | −$52.3M |
| FY18 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −4024.9% | −1106.7% |
| FY24 | −2469% | −3633.6% |
| FY23 | −1423.5% | −1416.2% |
| FY22 | - | - |
| FY21 | - | - |
| FY20 | - | - |
| FY19 | - | - |
| FY18 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | - |
| FY24 | −$80.9M |
| FY23 | −$79M |
| FY22 | −$80.3M |
| FY21 | −$116.6M |
| FY20 | −$76.3M |
| FY19 | −$49.6M |
| FY18 | - |
- Aligos Therapeutics
- Healthcare median
Show the numbers
| Year | Aligos Therapeutics | Healthcare median |
|---|---|---|
| FY25 | −1106.7% | −30.6% |
| FY24 | −3633.6% | −47% |
| FY23 | −1416.2% | −58% |
| FY22 | - | −80.4% |
| FY21 | - | −71.9% |
| FY20 | - | −62.2% |
| FY19 | - | −46.3% |
| FY18 | - | −49.6% |